Cayman Chemical Co.

Ann Arbor, MI, United States

Cayman Chemical Co.

Ann Arbor, MI, United States

Time filter

Source Type

Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L^(1), L^(2), L^(4), R^(1), R^(4), R^(5), R^(6), and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.


Disclosed herein are compounds of formula (I)^(1), L^(2), L^(4), R^(1), R^(4), R^(5), R^(6), and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.


Patent
Cayman Chemical Company and Myometrics, Llc | Date: 2017-06-07

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I)^(1), L^(2), L^(4), R^(1), R^(4), R^(5), R^(6), and s are as defined in the specification.


Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L^(1), L^(2), L^(4), R^(1), R^(4), R^(5), R^(6), and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.


Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM-utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding.


Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM-utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding.


Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D_(2 )mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).


Disclosed herein are compounds of formula (I) wherein L^(1), L^(2), L^(3), R^(1), R^(4), R^(5), and R^(6 )are as defined in the specification. Compounds of formula (I) are EP_(4 )agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.


Patent
Cayman Chemical Company Incorporated | Date: 2014-11-07

The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.


Patent
Cayman Chemical Company and Myometrics, Llc | Date: 2016-08-02

Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L^(1), L^(2), L^(4), R^(1), R^(4), R^(5), R^(6), and s are as defined in the specification.

Loading Cayman Chemical Co. collaborators
Loading Cayman Chemical Co. collaborators